vidarabine has been researched along with Anemia, Sickle Cell in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Brochstein, J; Sahdev, I; Stiles, J; Werther, N | 1 |
| Abraham, A; Cluster, A; Delgado, D; Hulbert, ML; Jacobsohn, D; Kukadiya, D; Murray, L; Shenoy, S | 1 |
| Bell, AD; Cheng, JC; Gutierrez, L; Karras, NA; Pawlowska, AB; Rosenthal, J; Sun, W; Wang, LD | 1 |
| Abu-Arja, R; Guilcher, GMT; Pai, V; Rangarajan, HG; Soni, S | 1 |
| Bruce, K; Domm, J; Evans, M; Frangoul, H; Isbell, J | 1 |
| Baker, C; Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Del Toro, G; Geyer, MB; Harrison, L; Jin, Z; Morris, E; Radhakrishnan, K | 1 |
| Agarwal, R; Ball, JB; Hutchinson, SK; Kharbanda, S; Lamb, LS; McKenna, DH; Smith, AR; Wagner, JE; Weinberg, KI | 1 |
| Baker, C; Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Del Toro, G; Garvin, J; George, D; Geyer, MB; Hawks, R; Jin, Z; Lee, MT; Licursi, M; Morris, E; Radhakrishnan, K; Satwani, P; Schwartz, J; Smilow, E; Zuckerman, W | 1 |
| Abraham, A; Benton, M; Brown, C; Chiang, KY; Dioguardi, JL; Grizzle, A; Haight, A; Hale, G; Horan, JT; Kanter, J; Kasow, KA; Nieder, M; Shelman, C | 1 |
| Amylon, M; Casella, JF; Chen, AR; Fuchs, EJ; Iannone, R; Jones, RJ; Storb, RF; Sullivan, KM; Walters, MC; Woolfrey, A | 1 |
| Blumberg, N; Fenton, P; Horan, JT; Liesveld, JL; Walters, MC | 1 |
| Chao, N; Chute, J; Essell, J; Gasparetto, C; Horwitz, ME; Long, G; Morris, A; Rizzieri, D; Spasojevic, I; Sullivan, K; Telen, M | 1 |
| Kim, HS; Niihara, Y; Yospur, L | 1 |
| Bartholomew, A; Chen, YH; Devine, S; Hoffman, R; Koshy, M; Peace, D; Sher, D; Sosman, J; Stock, W; van Besien, K | 1 |
| Kolb, HJ; Ledderose, G; Schlemmer, M; Schleuning, M; Stoetzer, O; Waterhouse, C | 1 |
| Cox, F; Hughes, WT; Meyer, D | 1 |
7 trial(s) available for vidarabine and Anemia, Sickle Cell
| Article | Year |
|---|---|
Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.
Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Prognosis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2020 |
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
Topics: Alemtuzumab; Anemia, Sickle Cell; Calcineurin Inhibitors; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Hydroxyurea; Male; Melphalan; Mycophenolic Acid; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2017 |
Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; beta-Thalassemia; Child; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Male; Melphalan; Mesenchymal Stem Cell Transplantation; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Unrelated Donors; Vidarabine | 2014 |
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.
Topics: Adolescent; Adult; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Prospective Studies; Siblings; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult | 2014 |
Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.
Topics: Adolescent; Allografts; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine | 2015 |
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Bone Marrow Transplantation; Child; Child, Preschool; Female; Graft Survival; Hematopoiesis; Humans; Immunocompetence; Kinetics; Male; Pilot Projects; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Combined Modality Therapy; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinopathies; Humans; Immunosuppressive Agents; Infections; Male; Pancytopenia; Thalassemia; Transfusion Reaction; Transplantation Chimera; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2005 |
9 other study(ies) available for vidarabine and Anemia, Sickle Cell
| Article | Year |
|---|---|
HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Cohort Studies; Dexamethasone; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Transplantation, Haploidentical; Transplantation, Homologous; Vidarabine; Young Adult | 2018 |
Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Mycophenolic Acid; Premedication; Tacrolimus; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy tbi and post transplant cyclophosphamide.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation; Young Adult | 2018 |
Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.
Topics: Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Graft Rejection; Graft Survival; Humans; Infant; Male; Myeloablative Agonists; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2013 |
Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.
Topics: Adult; Anemia, Sickle Cell; Directed Tissue Donation; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Kidney Failure, Chronic; Male; Myeloablative Agonists; Siblings; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Chronic lymphocytic leukemia in a patient with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Chronic Disease; Fatal Outcome; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1998 |
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Fatal Outcome; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Middle Aged; Nuclear Family; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2000 |
Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Cytomegalovirus in tears from patients with normal eyes and with acute cytomegalovirus chorioretinitis.
Topics: Adult; Anemia, Sickle Cell; Child, Preschool; Chorioretinitis; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Idoxuridine; Immunosuppression Therapy; Infant; Leukemia, Lymphoid; Leukemia, Myeloid; Lupus Erythematosus, Systemic; Male; Tears; Vidarabine | 1975 |